TrueLife - Jachym Fibir - Can Psychedelic Drugs Cure Alzheimer’s?

Starting point is 00:00:01 Darkness struck, a gut-punched theft, Sun ripped away, her health bereft. I roar at the void. This ain't just fate, a cosmic scam I spit my hate. The games rigged tight, shadows deal, blood on their hands, I'll never kneel. Yet in the rage, a crack ignites, occulted sparks cut through the nights. The scars my key, hermetic and stark. To see, to rise, I hunt in the dark, fumbling, fear. Hears through ruins maze, lights my war cry, born from the blaze.

Starting point is 00:00:40 The poem is Angels with Rifles. The track, I Am Sorrow, I Am Lust by Codex Serafini. Check out the entire song at the end of the cast. Ladies and gentlemen, welcome back to the True Life podcast. I hope everybody's having a beautiful day. I got an incredible guest for you today. Usually I would be talking to this gentleman. off in Europe somewhere,

Starting point is 00:01:19 in one country over there. He's always moving around. But today we got him live from San Francisco, the one and only. Yakem Fibir, the CEO of April 19th. He's in San Francisco, in the mix of all of it right there.

Starting point is 00:01:33 We're going to get to figure out what he's up to. We're going to talk about some latest magazine articles and the future of AI and drug design. I'm so excited. Yakem, thank you for being here today. What are you doing in San Francisco, my friend? Oh, George, you know, yeah, great honor actually to be here. I mean, I always love to talk to you.

Starting point is 00:01:53 And it's just like this cool space where we unwrap the super and super interesting layers of the psychedelic scene. And now even AI getting into that. It's just always great to be here. And so what brings me to the US and San Francisco is the on-deck founders program. So it's just like more, it's mostly about community and also educating people like to be able to run their own companies. And it's basically now first time after COVID in a real. real life. So it's been, you know, virtual for a very long time. And now it consists of like a month of different events and workshops about how to fundraise, how to, you know, do all the things,

Starting point is 00:02:59 startups. And have, so there's this space where I'm now in. It's in South Park, San Francisco. It's like a co-working space where people just get together, mingle and, and, and, and, find co-founders and, you know, scheme how to build their huge ideas. So, yeah, that's this one here. It's awesome to be here. Yeah. Congratulations on that. It sounds like an incredible place to do networking, to be around like-minded people that have similar passions. And, you know, I could imagine that there's a lot of camaraderie that's built there. And what a great place to to be at right now. yeah definitely can recommend even though it's more of a generalist thing so i'm kind of like a specific

Starting point is 00:03:49 niche of you know with april 19 who are designing all the psychedelics with AI and it's just like combination of so many things so but i can bake with people who do healthcare some people AI, some people do, you know, all these things. So it's just kind of like finding different people to talk to. And everyone can give you something. So, yeah, it's good. Does there seem to be a common thread there of like it's like if you look at the general population, it seems that the headlines are flooded with all these different ideas about

Starting point is 00:04:24 open AI or, you know, general AI and all these topics around AI. And I know that you're into that. Is that seem to be a thread that's running through the maker space or the on deck area that you're in right now? Yeah, I wouldn't say it's like a threat. I would say it's just like one of the main trends. So these people that are here, I would say that the main threat is just these kind of slightly crazy, you know, moonshot personalities trying to, trying to, you know, play it big. And a lot of them obviously see that AI is going to change a lot of things. So they're trying to, you know, incorporated into their ideas in one way or another.

Starting point is 00:05:09 Yeah, which is completely understandable. It's just this big regulation. It's going to change the way we work and how companies, you know, are able to do stuff in a more automated way. It's just, you know, much more efficient way that we're not able to reach previously. So yeah, it's a big, it's a big theme here. theme here but generally the community just it's selecting people based on the things that they've built and that they have the capacity to build great things and also about the spirit of service I would

Starting point is 00:05:53 say just you know it should be a community where the giving comes first so it's just not like okay like everyone's just working on their own idea and just you know trying to get as much you know information from the others but so that the people share um whatever expertise they have whatever you know tips and tricks uh whatever you know hardships they overcome and stuff like that and that really that really you can actually see here they have like an admissions process where they you know select you know from over a thousand people, just 120, so to be here. And it's, yeah, they really done a good job to get great people here. Yeah.

Starting point is 00:06:42 Well, it seems like it from, you know, I'm not even sure that where I'm going to take the wheel right here, but how about this? April 19th, Bicycle Day, a great company. you had a that day you become the CEO of a company like so much happened on that day right like throughout history throughout your life what a great day so let's just focus on the aspect of april 19th like what is april let's start off with what april 19th the day means to you and then we can move into what the company has got going on all right well i see that april 19th um is this almost like a mystical moment that created this

Starting point is 00:07:24 modern age myth. It's and there's actually people you know analyzing it from a religious perspective and it has a lot of things going on with other old age legends and so

Starting point is 00:07:42 to those who don't know what happened is that Albert Hoffman in Switzerland has been working on these new medicinal drugs And one day, I think it was 16th April, he, you know, just through manipulation, he managed to get a bit of, you know, LSD onto him, into him.

Starting point is 00:08:08 I don't know what happened exactly, but he felt this slight intoxication. I was like wondering, wow, could that be it? Could that have such effects in such small dose? And so he tried, like, what he thought was, like, very little amount. To his credit, it was. It was like 250 micrograms. So, yeah, he tried to basically drink it in a water solution. And then he just experienced a very strong trip, you know, like 250.

Starting point is 00:08:41 It's like a pretty good dose. Yeah, totally. And they didn't have cars. scars because this was wartime and so they had to take a bicycle to ride home with his assistant and so he had this really crazy experience riding a bike home totally tripping out and didn't know what was going on really and he had all these visions and all these distortions and everything and that was basically the story of bicycle day and and the implications of that story runs so deep into you know our entire culture i mean i could talk about you know how lSD has shaped um just you know the culture here in

Starting point is 00:09:37 san francisco you know the hippie culture and everything was like massive right and you know it was political and it was just you know entire war movements and and just like really really massive stuff going on as almost a direct consequence of experimenting with LSD here in research institutions. So, and yeah, that was this thing that, you know, they have taken it to be a medicine at the get-go, and they were sending it out to research institutions all across the world and in Czech Republic. Also, there was like a lot of people doing different experiment for therapy, for different mental disorders, for addiction, and just, you know, basic research into psychosis. They first call it like a psychotomimetic. So they are just approaching it in a way that this compound can replicate some of the positive symptoms of psychosis.

Starting point is 00:10:42 So they were just, you know, doing different experiments with that, not even in just therapy, but generally. And also in the nature of consciousness and other things. And really what's interesting about this is that when this happened, 1943, we had no idea about what serotonin receptors were, what serotonin was done. doing the brain, what kind of like role it played. And only after the psychomimetic effects of LSD were discovered, some other researchers, some years later, have connected that serotonin is found within the brain.

Starting point is 00:11:33 Sertanin is similar to LSD, and LSD is doing these, you know, weird facts on mental health and reception and so on. So they have actually connected CERC-Onen to play a role within, you know, mental health disorders and psychosis. And that actually kick-started the entire drug design of all those different drugs like antidepressant, antipsychotics, and a range of other, you know, what we now consider to be like classic treatments. And those are, you know, I dare to say hundreds of billions of, of, uh, of, uh, of, of, of drugs that is working on the certain own system. And that was actually started by that one trip on 19.

Starting point is 00:12:25 It's, you know, it's gargantuan. It's so amazing to think of. And when I'm glad that you were able to paint that story, because I didn't even understand how gargantuan that that moment was. And when you said it's, there's almost religious connotation to it. I've never stopped for a moment to think about what a modern day myth would look like or how a modern day myth would begin to manifest itself. But that is clearly the beginnings of a mythology that could be celebrated for a long time to come. And when you

Starting point is 00:12:59 start thinking about it, like it's kind of amazing to think that you could play a part in that mythology, right? And like that's kind of amazing. Isn't that crazy? Like that's what you guys are doing. It's fascinating to me. But I mean, we're kind of piggybacking this. All of us. All of us. But a walk-on part on the war is better than a lead role in a cage, right? True.

Starting point is 00:13:25 That's true. So how does that, so they go from like, we go from this idea of serotonin to SSRIs. And then we find ourselves in a world today where there's a lot of research coming out to say SSRIs, kind of like a placebo. Like they're not really as good as we thought they were. I'm not saying they don't work for some people and they haven't brought health or situations that make people's lives better. But it almost seems that this particular new movement going forward with, with, you know, especially psychedelics, that we're beginning to see new treatments coming out or beginning to see, you know, maybe this is a good segue into the Spanner magazine. Maybe we could talk a little bit about this article. that was in Spanner Magazine written by Chelsea Rixon,

Starting point is 00:14:14 doctors, drug dealers, or AI, who will win the race to treat dementia? I think that you're featured in this one. Yes, yes. So I'd like to just make this transition that I've taught about the role that CERCOLN played in all those different pathologies within the brain and mostly in mental health. And there's like a distinction. So obviously, a certain play some role. But humans have, you know, for various reasons,

Starting point is 00:14:52 jumped to very quick conclusions about how much they understand about this and the short stories that they didn't understand much when designing these drugs. They were just, you know, like shooting from the hip most of the time. you know, okay, had some effects. And the role with SSRIs you've been talking about, it was like they've seen some effects and they've seen some results. And then, you know, they made the connection to be almost, you know, as how to say it, so simple that it could really be communicated to the layman.

Starting point is 00:15:38 and to really people who were actual patients, the recipients. And they came up with this idea that, you know, you don't have enough of cert onin in your synapses, you have low cert onin. And these SSRIs, they're just, you know, through these mechanisms blocking the reptic inhibition, just increasing the amount of certain in your brain. And even without the reptic inhibition and all these things, you know, just basically saying, yeah, yeah,

Starting point is 00:16:08 I have low serotonin. That's why I have depression. It's going to increase your serotonin. Now you're good. Yeah, you're good. And it's just so simple and so effective. And that's why it solved so well. And that's why, you know, SSRIs were so successful and depression and so on. Well, the reality is that there are so many large-scale trials where Eshesis were no better than placebo. And it was just this ridiculous. moments sometimes where, you know, okay, so as SARS were taken as a standard of care and then some people try to make something better than SSR rights and then you do a clinical trial

Starting point is 00:16:51 and, you know, the necessaries don't work actually and your other drug, you know, may not work or may work, whatever, but you know, you just have this, you know, standard of care and it's actually shit. That happened a lot of times. So it's like, it was always like questioned this, you know, hypothesis that SSRs, you know, are targeting the mechanism of depression what's causing it. And lately, you know, as we understand much more, this has been really questioned from different angles. And yeah, it's much more leaning towards the hypothesis that depression and other things are being caused by pathological.

Starting point is 00:17:37 configuration of our brain pathways and what we've kind of built up to be our thought patterns and ways of, you know, processing information and thinking about things. And when we, when we arrive to some, you know, dysfunctional ones and we kind of internalize them, we kind of make them stronger, we make them automatic, then that leads to depression. And so that's why psychedelics, by being able to kickstart monoplasticity can have such a great effect. And turning over to this banner article, and what we're doing with April 19 is like, we're thinking that secularists can go even further and not just change and help us heal or make right the pathways that correspond to thought patterns and so on that are

Starting point is 00:18:33 cause of mental health disorders. but we think they might be useful in actually healing even the brain damage by neurodegeration. And this has been kind of like really strongly, you know, a strong validation was coming from this case study that actually was shared by Adam Tapp. He has his own podcast tapped into psychedelics. and I've my episode talking with him is coming up but he

Starting point is 00:19:10 basically has this like super interesting story with his father and you know he asks everyone to share that so that's why we've done the article he his father basically

Starting point is 00:19:25 was over a period of 10 years slowly declining with its cognitive abilities and slowly getting worse you know, forgetting things. And when it got to a point where he was really like repeating the same question like 20 times and it's just very, very dysfunctional. They diagnosed him and it was classic Alzheimer's supposed to for top protein. And, you know, Dr. Sere has been, it's about six months until he needs to be in a long-term care facility.

Starting point is 00:19:59 And so that's when, you know, Adam was like, okay, so. there's not much to lose right so let's try at least something that you know he's had experience with uh having healing properties personally um and a lot of experiences uh so adam tabb is like he's eaten 42 grams of mushrooms with his life each eating 40s two grams is like wow i can't imagine i can't imagine so he he's the expert yeah right But they tried macrodosing sauce, and it wasn't doing much with mushrooms. But then because he has seen some pre-conlical studies on neuroplasticity

Starting point is 00:20:46 with 5-0 DMT and a bit more complex effects on neuroplasticity, and that's what we're focusing on with April 19, by the way. So he tried to, you know, microdose that, but it's not overly available, so he needed to make a nasal spray. And even though it was a bit difficult because, you know, as a nasal spray, it's like a very intense, even in low doses and it produces this, you know, body load and, you know, kind of, it's like, you're not fully on tripping, but your feelings like slightly, this is the come up. And, you know, for example, for a person going through severe, you know, neuroduration, it's,

Starting point is 00:21:30 It was a bit tricky, but they persevered, those in twice a day for, and after four months. They've done this reassessment. It was just because it's slowly getting better. And he's just like this amazing improvement in cognitive skills. He just, you know, his cognitive score test went from 53 to 83 out of 100 at the Edinburgh scale.

Starting point is 00:21:54 And basically then he slowly got better. you started, you know, play cards with them, play guitar, started seeing as grandkids, and essentially, like, being yielded Alzheimer's. It's just like a normal old person now. So, yeah, like, we've never seen any kind of anything close to that in Alzheimer's. It just slows it down and it only slows it down when it's the very early stages, but that this was actually kind of advanced. So the implications of this, if we could replicate this,

Starting point is 00:22:33 obviously it's just one case study. So I'm just always taking caution to make some, you know, sweeping generalization. This could be huge. And really what may be the mechanism of action behind this, It's that as your neurons die out in this neurodeteration, there are some different cause. For example, in Alzheimer's, it's the buildup of faulty, folded proteins. Then in a normal, like, living brain, the surviving neurons kind of make more connections between themselves to take up the function of the dead neurons.

Starting point is 00:23:25 That's what happens in a healthy brain. But when the speed of neurons dying gets too fast, you know, you don't have enough time for these neurons to take over. And by increasing neuroplasticity of these neurons, so the rate at which these neurons branch out and make connections, make synaptic connections between themselves, this actually, you know, is faster than the, the rate of the neurons dying. And so you're able to kind of build out these pathways and restore function even when in the places where the neurons are already died out. And that is just like it makes you know sense. So it's just like it's possible that we we've seen the effect. There's a possible explanation for that. And and then there's this like execution of like how do we get this to patients and you know how to we ensure that this is like a

Starting point is 00:24:30 um reliable treatment for patients right so um and that also lies within the structural five male DMT it's connected to the tolerance buildup um but there's other things i don't want to really go too deep into this i'm happy to you know talk to anyone who reaches out but one of the big things why salocybin didn't work and five nine empty did work is that B-HMOD-MT does not cause as rapid tolerance build up as Cyl-7. So if you were to do C Cyl-S-S-7, the same dose, you know, every day, slowly, you know, the fact is going to decrease. And that's because it causes B2DIC recruitment and receptor down regulation,

Starting point is 00:25:17 basically just reducing the population of your serotonergic, your 5H2A neurot receptors. and they don't have enough time to renew. You have to wait a couple of days. That's why the microdosing regimes have some free days between them. And 5MDMT does not do that and DMT also doesn't. So for some reason, it's really based on their structure, they don't cause as much of VETIRA recruitment

Starting point is 00:25:50 and they can be dose, you know, there's just very short-term tolerance like an hour with DMT for not much longer with 5M2DMT so that you can really do like twice a day and you can have this constant effect over months that's just continually driving the normalisticity and so on and this is probably crucial I mean there's this you know a downside to that that DMT and 5M0D2 very short half life and that's this is like you're you need to like with DMT it would be pretty hard if you were to smoke it or you would have to you know do some you know ayahuasca kind of thing you just you know that has other effects on your

Starting point is 00:26:36 digestion and other systems in your brain so not very good for you know for vulnerable neurodeteration patients and and you know so um in the ideal world you would have a thing that would last on be orally bioavailable you can you can could just eat it once a day with your other pills, supplements, and just, you know, have this constant effect. And this is what we're focusing on with April 19. Just, you know, we would think there's just completely reasonable to do it, especially with the AI and drug design that we have, you know, now it's super powerful. It's just about optimizing some properties of those compounds and how they find how they metabolize and how they absorb.

Starting point is 00:27:25 And that's what we've done with so many compounds in different other classes before. It can be done with this as well. Yeah. Just need some time and money. Man, it brings a smile to my face. And I'm so happy to hear, I'm so happy to hear that story and to see that people are taking, you know, the idea of solving Alzheimer's serious. It seems for so long it was like this black hole that there's nothing we can do and I'm curious though like You know, there's often a thing that says like how do you manage what you can't measure? Is there some neurofeedback

Starting point is 00:28:08 Imaging that shows some of these these neurodegenerative diseases getting better or Obviously you can tell when someone is able to play guitar who a few months ago was Continually telling the same story or forgetting the same name so we can see that as a measurement But are there other ways to measure like a Q-E-E-G machine or is there some kind of neural imaging that would go along with measuring this? Yeah, I mean, it's funny that you should ask, but it's a really great question. And it's interesting that there was a person here at On Tech, and she had a lot of experience in the health tech. And this was her first question, right? Did you make brain images?

Starting point is 00:28:52 you make brain scans, not really, but if you did brain scans, then that will be something, you know, then that would be like a confirmation, right? And so, yes, actually there is, there's different ways how to see the degree of neurodegeneration play out within the human brain in Alzheimer's, you know, how to see the deposits of those faulty, badly folded proteins. And, you know, this function of the connections on the higher level. So, yeah, I guess that would be something really interesting for researchers to look into. The for me, so I see that, you know, 5M2DMT is obviously something to definitely go after in neurodegeneration. Like this is like available here.

Starting point is 00:30:03 Let's let's just do it. And I mean, if anyone from Beckley-Sytec is listening to this, they are, so they're developing nasal spray with 5-0-DMtmt, but they're doing like much higher dosages. and the indication is a depression. And so it's just still psychotherapy. And I would like to tell them that, you know, they should just pivot towards nervous and focus on that instead. Yeah. And the idea is that I would really like to just go with Patneot DMT.

Starting point is 00:30:49 But what I know is that it is super hard to get an unpretentable and, you know, already, you know, broadly patented thing to the market. So just like us, we would not be able to raise funding to do that. So, you know, back beside it can. and we understand as a company that it's like almost assured that 5-MOTD is going to be first in class for these for this you know for these indications but long-term game is not going to be you know best in the class because exactly you know this is just you know nasal spray and you know they are not even sure like

Starting point is 00:31:44 okay this is an open question whether what they're developing is basically a nasal spray but in an inpatient setting with like controlled setting with a therapist that's out there to assist right and so what happens to be

Starting point is 00:32:05 kind of like what we don't know is whether it will be safe enough to be used in the lower dosages in outpatient setting because you know there are these you know acute sacriolic effects especially the nasal spray is like the fastest way to your brain and it's like yeah it gets where it's supposed to go but it just gets there like really quickly and really you know really there's just this bump with the sacrileic effects and and instead of something which you would like to have it's just like slow onset of, you know, slow effect, you know, constant effect to heal the brain over a long

Starting point is 00:32:50 term. So it looks like we lost him for a moment, but he'll be back shortly, I believe. It's fascinating to think about the ways in which psychedelics can have ways to heal the brain. And for those who are just listening, the article is from a Spanner magazine. And it's a fascinating article that talks about a gentleman who is able to pretty much cure his neurogenitorive diseases. And I want you to think about everybody here probably knows someone who has gone through it, was going through it, or has gone through it. And think about how much destruction that does to the family. When you see somebody you loved who can no longer remember the things that they love. It's heartbreaking.

Starting point is 00:33:57 It's heart-wrenching. And especially for the person that's going through it. If you look at the communities we live in and the countries we live in, the aging demographics proves that this is going to become an epidemic in the future unless we figure out ways to make it better. And I think what the people like Yachem and AI or April 19th and Beckley and the people in the world of psychedelics are doing is they're finding real connections that can in fact begin to solve these problems.

Starting point is 00:34:26 But I think it goes much deeper than that. I think what we're going to see is a move from healing to optimizing. And I want everyone just to take a moment to think about that. What is the difference between healing and optimizing? Healing kind of has this idea that you're sick, you're not well, and then when you heal, you get back to a baseline. Optimization has this similar feel, but you go from baseline to better. And so I don't think it's too far of a strong.

Starting point is 00:34:56 stretched to see these technologies, to see these substances being rolled out into the world of healing, into the world of medicine, and you begin to see people getting better. But I think you're going to see a step up from healing into optimization. And we had previously talked about doing brain scans to show the way in which the neuroplasticity is happening, to show ways in which the brain is functioning. And that's good. But those are mostly something that's needed for insurance companies, clinical trials, and things like this. I think that the ultimate proof in any sort of example like this might be the warm, healthy, happy tears of the loved ones.

Starting point is 00:35:39 And what I mean by that is imagine seeing somebody you loved who's suffering from a neurodegenerative disease and then see them get better. For a lot of us, you know, it gives me goosebumps thinking about it. And if you've had someone in your life that has suffered from this, you know it's this slow death. Like you're watching somebody die even though they still have a heartbeat. You're watching somebody die even though they can still have a voice. And I think that the promise of these types of psychedelics, especially the AI-driven psychedelic drug design, which Yahim and April 19th are working on, is a future where we can begin to experience a quality of life in elder care that has not been done before.

Starting point is 00:36:27 It does beg some interesting questions. How much money goes into elderly care? If I were to put on my finance hat, which I don't know anything about finance, so take this with a grain of salt, but I don't think that that community goes quietly. I think that the world of legacy drug design, the world of medicine that the boomers are used to, I think that they fight tooth and nail

Starting point is 00:36:56 to keep the ideas of the psychedelic medicine out of the hands of most people. I know it's sad to say, but think about how much health care, how much money goes into healthcare. Think about all these different old folks homes. And as for us, like we would love to see the people in these homes

Starting point is 00:37:13 be in a position where they could take care of themselves. But I just, and I hesitate to say this, but I think that the money built up in that industry doesn't go quietly. I think that there will be fights in court for it. I think that there'll be a lot of pushback on safety especially. I think that safety will be the Trojan horse they try to fight with. But ultimately, the results should lead the way to healing. And if the article produced by Adam Tapp in April 19th in Spanner Magazine by Chelsea Rixon, if that article can continue to ring true, and we can continue to hear more stories like this,

Starting point is 00:37:56 and we can continue to see the different types of healing that happens, I think that we are headed for a world that is not only more beautiful than you imagine, but more beautiful than you can imagine. It brightens up the potential future for the way. world of health care, for the world of aging, for the world of learning, for the world of mentors. Imagine if some of the people who are the oldest among us were able to keep their faculties longer, what they could do to teach people. It's almost like a rebirth. It's almost as if they're given their life back so that they can give back more to the community. It does opening up interesting

Starting point is 00:38:37 questions, though. What about somebody who's on social security or, has a pension. What if they live to be 140? What does the money come from to do that? So it does open up these other questions. But I think it's exciting. And I think it's a great potential for the future. And I really think that the world we live in, I think that the world we live in, I just got a message from Yachem, and he is having some hot spot troubles. And this is kind of funny because before we got started, we were having a quick talk about technology. and how you should always expect technology to fail when you're in the midst of recording something. And lo and behold, it happens.

Starting point is 00:39:20 So let me just continue on with what I think you may see in the future. I think that the struggle is real. I think that you are going to see better drug designs with AI. If we look at the way in which chat GPT, open AI, all these different companies are beginning to use this AI software to rediscover what. as possible, the next frontier has to be medicine. And, okay, I'm going to say something sad right here, but the state of medicine, even though we live in the 21st century, you know, we're beginning to see that a lot of the drugs we've had were no better than placebos.

Starting point is 00:39:58 In fact, everybody understands the placebo effect. You give one person a pill and one person a sugar pill. And most of the times, the placebo works just as good. So we're understanding that the power of the mind has the power to heal. But what happens when we were able to? use the power of artificial intelligence. What happens when we can scrape the world of information for the best possible drug design, test out those drug designs with a similar AI system, and then take the best of the best and then begin trials with that? That should speed up the

Starting point is 00:40:29 ability to make really change, to make real change real fast. We should be able to move years in advance using this kind of technology. Like I said, there will be a pushback when it comes to safety in my opinion. But the future is really bright. The future, even though we appear to be on the cusp of world war or financial collapse or choose your calamity, whatever fear porn that is being pushed your way, it is just that. It's just fear. And it's just being pushed at you because we are on the cusp of transcending the world we used to know. We are beginning to see the institutions that told us they know everything failed. We are beginning to see the world of authority crumble in the world of community beginning to be built all around us.

Starting point is 00:41:19 And I would like to employ every one of you listening to this to do your best to become the very best that you can be. Live your best life now. And if that means walking away from something that you're not happy about, find the courage to do it. And your family will be better and you'll be better. And the life that you live will be better. We'll probably end it up here coming shortly. We're coming up on about 40 minutes. But I want to say that everyone should go check out, check out Yackem and his company April 19th.

Starting point is 00:41:52 He's actually at an incredible spot right now in San Francisco, meeting with all these different founders. The world of psychedelic medicine is really moving forward. And there's a lot of interesting studies. There's a lot of interesting people. and if you're curious about any of this, you could reach out to me, definitely reach out to April 19th the company, look and see what they're doing, look in your community. What can you do to make the world a little bit better and understand that the psychedelic experience may be right for you.

Starting point is 00:42:20 And if it is, you should explore it and explore the world you live in and try to make everyone around you better and know that the True Life podcast is here for you. I love you guys. I hope everybody's having a beautiful day. And I'm probably, I'm going to be on a lot more with you on him. So let's wish him well. I hope you're good out there, buddy. We love you.

Starting point is 00:42:37 And thank you for doing what you're doing. Looking forward to seeing you on the Adams podcast. And to everybody out there, I hope you have a fantastic day. Aloha.

TrueLife - Jachym Fibir - Can Psychedelic Drugs Cure Alzheimer’s?

There aren't comments yet for this episode. Click on any sentence in the transcript to leave a comment.